LifeMine Raises $263M to Advance LIFE-001 Transplant Therapy
WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
SHANGHAI, China, June 15, 2026 CARsgen Therapeutics Holdings Limited has unveiled encouraging clinical data for its investigational allogeneic CAR...
NEW YORK and ATHENS, Greece, June 13, 2026 Kos Biotechnology Partners has announced the successful third closing of its...
NEW YORK & CAMBRIDGE, Mass., USA, March 30, 2026 Blackstone has announced the final close of Blackstone Life Sciences...
